logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11359012 B1

PDFFull Text
Date of Patent:
Jun. 14, 2022

Filed:

Aug. 27, 2021

Specific chimeric antigen receptor cells targeting human cldn18a2, preparation method and application thereof

Applicant:

Nanjing Kaedi Biotherapeutics Ltd., Nanjing, CN;

Inventors:

Hongjiu Dai, Nanjing, CN;

Hui Xu, Nanjing, CN;

Jingjing Zhu, Nanjing, CN;

Mengyao Wang, Nanjing, CN;

Assignee:

NANJING KAEDI BIOTHERAPEUTICS LTD., Nanjing, CN;

Attorney:

Bayramoglu Law Offices LLC

Primary Examiner:

Ruixiang Li

Int. Cl.
CPC ...
C07K 16/28 (2006.01); C12N 5/0783 (2010.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); A61P 35/00 (2006.01); C12N 15/86 (2006.01); A61K 39/00 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/28 (2013.01); A61P 35/00 (2018.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70578 (2013.01); C12N 5/0636 (2013.01); C12N 15/86 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); A61K 2039/5156 (2013.01); A61K 2039/5158 (2013.01); C07K 2317/569 (2013.01); C07K 2317/622 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01); C12N 2510/00 (2013.01); C12N 2740/15043 (2013.01); C12N 2740/15071 (2013.01);
Abstract

A chimeric antigen receptor (CAR) cell specifically targeting human Claudin18.2 (CLDN18A2), a preparation method and an application thereof are provided. The extracellular binding region of the CAR includes a protein specifically recognizing CLDN18A2 that has any one of the amino acid sequences as shown in SEQ ID NOS: 2-5 or any one of the amino acid sequences of the variants having 70%-99% identity with the amino acid sequences shown by the SEQ ID NOS: 2-5. The immune effector cell modified by the CAR can be used to treat tumors.

Find Patent Forward Citations

Dai, Hongjiu. (2022). Specific chimeric antigen receptor cells targeting human cldn18a2, preparation method and application thereof (U.S. Patent No. 11359012). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/11359012

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…